Breast Positioning Articles & Analysis
20 news found
Dirbas in 2002 was an early adopter of accelerated, partial breast irradiation for surgical patients with early-stage breast cancer and served as Primary Investigator (PI) on Stanford’s successful investigator initiated APBI trial: he has also served as site-PI for other cooperative group trials related to breast cancer. ...
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of ...
(Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: Phase III clinical trial, Flamingo-01, has officially started Multiple sites have begun the screening and enrolling ...
” About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2/neu positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant ...
Patients with incurable breast cancer could potentially benefit from new Welsh-led research, latest evidence suggests. ...
The team running the country's largest breast screening programme have shown that using Transpara breast AI further confirmed the enormous contribution of this technology to breast cancer detection: not only to reduce the number of false positives but also to reduce radiologists' workload by over 60%. ...
In certain cancer types, such as HER2-positive breast cancer, immunohistochemistry (IHC) analyses will also be performed to measure protein expression and reveal patients eligibility to anti-cancer drugs. ...
Like many innovations that have supported better clinical and financial outcomes over the years, artificial intelligence (AI) is making an impact on radiology practices: reducing reading time, increasing cancer detection, and reducing false positives in breast cancer detection. AI is also bringing clinicians and specialties together to extend the value of ...
Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy Exact Sciences Corp. ...
Daugherty is expanding his role with a very significant commitment to serve as medical monitor of our upcoming and future clinical trials as we seek to expand GP2’s potential to all HER2 positive breast cancer patients and to explore HER2 low breast cancer and other HER2 expressing cancers. ...
(NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial were published in The New England Journal of Medicine. ...
Of over 100 applicants, Koning is one of only ten companies that has been chosen and will showcase the Koning Breast CT - a technology that will change millions of women’s lives around the world through no compression, low dose, and true 3D imaging. ...
Food and Drug Administration (FDA) for pegloprastide (AVB-620) for the intraoperative detection and visualization of positive margins during breast cancer surgery. Pegloprastide is designed to deliver a fluorescent marker to cancer cells to aid surgeons in identifying positive margins in real time during surgery. Positive margins ...
First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio Breast Cancer Symposium RxPONDER results from over 5,000 women likely to transform the treatment of node-positive breast cancer, as the TAILORx study did in node-negative disease Exact Sciences Corp. (NASDAQ: EXAS) ...
Introduction Anliprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive and later evaluated in phase II studies for metastatic breast cancer. ...
In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer treated with ENHERTU, ILD occurred in 9% of patients. ...
Data obtained in real-life setting from more than 800 patients with node-negative or nodepositive early-stage breast cancer highlight the test’s impact on clinical practice with chemotherapy-sparing effect Publication of landmark TAILORx study results led to greater reduction in chemotherapy recommendations Exact Sciences Corp. today announced results from a ...
We believe this robust body of evidence will help to position the Imagio system as a sound diagnostic tool for the breast imaging community. ...
Among women with a family history of breast cancer, those who worked with organic solvents prior to their first full-term birth had an increased risk for hormone receptor-positive breast cancer, according to data published in Cancer Research, a journal of the American Association for Cancer Research. ...
Among women with a family history of breast cancer, those who worked with organic solvents prior to their first full-term birth had an increased risk for hormone receptor-positive breast cancer, according to data published in Cancer Research, a journal of the American Association for Cancer Research. ...